Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis

被引:1
|
作者
van Husen, Georg [1 ]
Virdone, Saverio [2 ]
Pieper, Karen [2 ]
Kayani, Gloria [2 ]
Fox, Keith A. A. [3 ]
机构
[1] Tenac Io, Oberwallstr 6, D-10117 Berlin, Germany
[2] Thrombosis Res Inst, Dept Stat, London, England
[3] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
来源
关键词
Atrial fibrillation; Universal Clinician Device; Management guidelines; Diabetes; Personalized medicine; Risk prediction; CARDIOVASCULAR OUTCOMES; WARFARIN; STROKE; EMPAGLIFLOZIN; MORTALITY;
D O I
10.1093/ehjdh/ztac011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Atrial fibrillation (AF) management guidelines advise using risk tools to optimize AF treatment. This study aims to develop a dynamic and clinically applicable digital device to assess stroke and bleeding risk, and to facilitate outcome improvements in AF patients. The device will provide tailored treatment recommendations according to easily attainable individual patient data. Methods and Results This Universal Clinician Device (UCD) was created using the GARFIELD-AF registry using a split sample approach. The GARFIELD-AF risk tool was adapted with two modifications. First, predictors with >= 1000 missing data points were separated, allowing expected risks estimation. Second, recommendations for modifiable risk factors and associated 2-year outcome estimates were incorporated. Outcomes of interest were all-cause mortality, non-haemorrhagic stroke/systemic embolism (SE), and major bleeding. All patients were randomized to a derivation (n=34853) and validation cohort (n=17165). In the derivation cohort, predictors were identified using least absolute shrinkage and selection operator regression. Cox models were fitted with the selected parameters. The UCD demonstrated superior predictive power compared with CHA(2)DS(2)VASc for all-cause mortality [0.75(0.75-0.76) vs. 0.71(0.70-0.72)] and non-haemorrhagic stroke/SE [0.68(0.66-0.70) vs. 0.65(0.63-0.67)], and with HAS-BLED for major bleeding [0.69(0.67-0.71) vs. 0.64(0.62-0.65)]. Universal Clinician Device recommendations reduced all-cause mortality (8.45-5.42%) and non-haemorrhagic stroke/SE (2.58-1.50%). Patients with concomitant diabetes and chronic kidney disease benefitted further, reducing mortality risk from 13.15% to 8.67%. One-third of patients with a CHA(2)DS(2)VASc score of >1 had the lowest risk of stroke. Conclusion The UCD simultaneously predicts mortality, stroke, and bleeding risk in patients using easily attainable individual clinical data and guideline-based optimized treatment plans. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF: NCT01090362
引用
收藏
页码:181 / 194
页数:14
相关论文
共 50 条
  • [31] Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation The Loire Valley Atrial Fibrillation Project
    Banerjee, Amitava
    Fauchier, Laurent
    Bernard-Brunet, Anne
    Clementy, Nicolas
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (03) : 549 - 556
  • [32] Targeting stroke risk and improving outcomes in patients with atrial fibrillation in Latin America
    Stambler, Bruce
    Scazzuso, Fernando
    SAO PAULO MEDICAL JOURNAL, 2016, 134 (06): : 534 - 542
  • [33] Evaluation of atrial fibrillation management and cardiovascular risk profile in atrial fibrillation patients: A cross-sectional survey
    Rackauskas, Gediminas
    Zabiela, Vytautas
    Marinskis, Germanas
    Baranauskas, Arvydas
    Balkute, Deimile
    Alunderyte, Justina
    Puodziukynas, Aras
    Kazakevicius, Tomas
    Kviesulaitis, Vilius
    Aidietis, Audrius
    MEDICINA-LITHUANIA, 2017, 53 (01): : 19 - 25
  • [34] Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
    Archibald, William J.
    Rabe, Kari G.
    Kabat, Brian F.
    Herrmann, Joerg
    Ding, Wei
    Kay, Neil E.
    Kenderian, Saad S.
    Muchtar, Eli
    Leis, Jose F.
    Wang, Yucai
    Chanan-Khan, Asher A.
    Schwager, Susan M.
    Koehler, Amber B.
    Fonder, Amie L.
    Slager, Susan L.
    Shanafelt, Tait D.
    Call, Timothy G.
    Parikh, Sameer A.
    ANNALS OF HEMATOLOGY, 2021, 100 (01) : 143 - 155
  • [35] Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
    William J. Archibald
    Kari G. Rabe
    Brian F. Kabat
    Joerg Herrmann
    Wei Ding
    Neil E. Kay
    Saad S. Kenderian
    Eli Muchtar
    Jose F. Leis
    Yucai Wang
    Asher A. Chanan-Khan
    Susan M. Schwager
    Amber B. Koehler
    Amie L. Fonder
    Susan L. Slager
    Tait D. Shanafelt
    Timothy G. Call
    Sameer A. Parikh
    Annals of Hematology, 2021, 100 : 143 - 155
  • [36] Identifying patients at risk for atrial fibrillation in the community: a systematic review and meta-analysis of prediction models
    Himmelreich, J. C. L.
    Veelers, L.
    Lucassen, W. A. M.
    Van Weert, H. C. P. M.
    Harskamp, R. E.
    EUROPEAN HEART JOURNAL, 2019, 40 : 271 - 271
  • [37] OPTIMAL BLOOD PRESSURE AND CARDIOVASCULAR RISK MANAGEMENT IN PATIENTS WITH ATRIAL FIBRILLATION
    Lip, Gregory
    JOURNAL OF HYPERTENSION, 2023, 41 : E32 - E32
  • [38] Nonpharmacological Management of Atrial Fibrillation in Patients at High Intracranial Hemorrhage Risk
    Gurol, M. Edip
    STROKE, 2018, 49 (01) : 247 - 254
  • [39] An analysis of risk factors for stroke in atrial fibrillation and hypertension patients
    王娟
    China Medical Abstracts(Internal Medicine), 2014, 31 (02) : 95 - 96
  • [40] Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease
    Benz, Alexander P.
    Healey, Jeff S.
    Chin, Ashley
    Commerford, Patrick
    Marsden, Tamara
    Karthikeyan, Ganesan
    McIntyre, William F.
    Wong, Jorge A.
    Damasceno, Albertino
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Wallentin, Lars
    Ezekowitz, Michael D.
    Eikelboom, John W.
    Yusuf, Salim
    Connolly, Stuart J.
    CARDIOVASCULAR RESEARCH, 2022, 118 (01) : 295 - 304